From The American Journal of Managed Care, "On the Horizon for Multiple Myeloma"

Article

This article-written by Michael Marlan Mohundro, PharmD; and Brice Labruzzo Mohundro, PharmD-highlights the multiple available regimens for patients with relapsed or refractory myelomas as well as new treatments that are currently being investigated in clinical trials.

This article—written by Michael Marlan Mohundro, PharmD, and Brice Labruzzo Mohundro, PharmD—highlights the multiple available regimens for patients with relapsed or refractory myelomas as well as new treatments that are currently being investigated in clinical trials. The new regimens discussed include proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors.

See the article, “On the Horizon for Multiple Myeloma,” from The American Journal of Managed Care in its entirety here.

Related Videos
cancer pain management | Image Credits: © Burlingham - stock.adobe.com
multiple myeloma clinical trial daratumumab/ Image Credits: © Dragana Gordic - stock.adobe.com
multiple myeloma clinical trial/Image Credits: © Studio Romantic - stock.adobe.com
3d rendered illustration of lung cancer 3D illustration - Image credit:  appledesign | stock.adobe.com
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.